Hajra Nashin

Associate
Full contact info

Experience

Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion

December 20, 2022

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

 

Read more

Related contacts

Barbara Borden
Partner, San Diego
Kay Chandler
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Rowook Park
Partner, San Diego
Jacqueline Grise
Partner, Washington DC
Kelly Murata
Paralegal Specialist, San Francisco
Michael Tollini
Partner, Washington DC
Todd Gluth
Partner, San Diego
Lindsey O'Crump
Associate, Washington DC
Edmond Lay
Associate, San Diego
Vivian Tsai
Associate, Los Angeles Santa Monica
Melissa Meza
Associate, San Diego
Peter Adams
Partner, San Diego
Fraser Brown
Partner, Washington DC
Ross Eberly
Partner, Los Angeles Santa Monica
Patrick Van Eecke
Partner, Brussels
David Fletcher
Partner, Washington DC
Caroline Hobson
Partner, London
Alexander Israel
Partner in Charge – Brussels, Brussels
Christopher Kimball
Partner, Washington DC
Mischi a Marca
Partner, San Francisco
Chadwick Mills
Partner, San Francisco
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
John Paul Oleksiuk
Partner, New York
Michelle Garcia Schulman
Partner, Reston
Lei Shen
Partner, Chicago
Charity Williams
Partner, San Diego
Elizabeth Anne Wright
Partner, Brussels
David Burns
Special Counsel, Washington DC
Sharon Connaughton
Special Counsel, Washington DC
Christine Graham
Special Counsel, London
Natasha Leskovsek
Of Counsel, Washington DC
Rebecca Ross
Special Counsel, Washington DC
Stella Sarma
Special Counsel, Brussels
Matthew D. Silverman
Special Counsel, San Diego
Karen Tsai
Special Counsel, Washington DC
Karun Ahuja
Associate, Chicago
Wade Andrews
Associate, San Diego
Ajay Athavale
Associate, San Francisco
Anna Caro
Associate, London
Umer Chaudhry
Associate, Washington DC
Megan Drill
Associate, San Diego
Andrea Batalla Eguidazu
Associate, London
Michael Fernando
Associate, London
Daniel Gillon
Associate, San Diego
Zack Gong
Associate, Shanghai
Ellie Guadiana
Partner, Los Angeles Santa Monica
Justin Kisner
Special Counsel, Palo Alto
Jessica Koffel
Associate, Brussels
Allison Kutner
Associate, New York
Daniel Lac
Associate, San Diego
Jan Lang
Associate, Brussels
Katie MacDowell
Associate, Reston
Joe Mandry
Associate, San Diego
Hajra Nashin
Associate, San Diego
Dani Nazemian
Special Counsel, San Diego
Linh Nguyen
Associate, San Diego
Allison Wettstein O’Neill
Associate, San Diego
Alexandra Paterson
Associate, London
Addison Pierce
Associate, Chicago
Bartholomäus Regenhardt
Associate, Brussels
Arman Sagart
Associate, San Diego
Grant Schweikert
Special Counsel, Washington DC
Michael Weinstein
Associate, San Diego
Nathaniel Hearn Jr.
Associate, New York
Megan Browdie
Partner, Washington DC

Related Practices & Industries

Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche

August 6, 2022

Cooley advised Poseida Therapeutics, a clinical-stage biopharmaceutical company, on its strategic collaboration and license agreement with Roche. Lawyers Ken Krisko, Marya Postner, Bin Wang, Hajra Nashin and Brendan Haberle led the Cooley team advising Poseida. 

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Marya Postner
Partner, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Hajra Nashin
Associate, San Diego
Brendan Haberle
Associate, San Diego
Edmond Lay
Associate, San Diego
Tom Coll
Partner, San Diego
Sharon Connaughton
Special Counsel, Washington DC
Jacqueline Grise
Partner, Washington DC
Amanda Pacheco
Associate, Palo Alto
Jeffrey J. Tolin
Partner, New York
Ivor Elrifi
Partner, New York
Matthew Pavao
Partner, Boston
Rachel Thorn
Partner, New York
Natasha Leskovsek
Of Counsel, Washington DC
Liza Cotter
Associate, Boston
Yasmin Roland
Associate, Brussels
David Navetta
Partner, Colorado
Patrick Van Eecke
Partner, Brussels
Maricel Mojares-Moore
Special Counsel, San Francisco

Related Practices & Industries

Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion

June 4, 2022

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Read more

Related contacts

Barbara Borden
Partner, San Diego
Rowook Park
Partner, San Diego
Charles Bair
Partner, San Diego
Lindsey O'Crump
Associate, Washington DC
Vivian Tsai
Associate, Los Angeles Santa Monica
Melissa Meza
Associate, San Diego
Kay Chandler
Partner, San Diego
Alessandra Murata
Partner, Palo Alto
Ross Eberly
Partner, Los Angeles Santa Monica
Koji Fukumura
Partner, San Diego
Phil Mitchell
Partner, New York
David Navetta
Partner, Colorado
Todd Gluth
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Matthew D. Silverman
Special Counsel, San Diego
Stella Sarma
Special Counsel, Brussels
Christine Graham
Special Counsel, London
Brendan Haberle
Associate, San Diego
Hajra Nashin
Associate, San Diego
Megan Drill
Associate, San Diego
Heidi E. Wang
Associate, San Diego
Eileen Leman
Associate, Los Angeles Downtown
Daniel Gillon
Associate, San Diego
Wade Andrews
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Jennifer Shanley
Special Counsel, New York
Daniel Lac
Associate, San Diego

Related Practices & Industries

Immatics Enters Global Exclusive License Agreement With Bristol Myers Squibb

December 22, 2021

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
Carly Robinson
Associate, Reston
J. Brian Stalter
Special Counsel, New York
Stephanie Parker Palmer
Special Counsel, Reston
Nicollette R. Kirby
Associate, Washington DC
Alexander Israel
Partner in Charge – Brussels, Brussels
Jan Lang
Associate, Brussels
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Partner, New York
Patrick Van Eecke
Partner, Brussels
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Special Counsel, Brussels
Christine Graham
Special Counsel, London
Hajra Nashin
Associate, San Diego
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Nykode Therapeutics Enters Collaboration Agreement with Regeneron

November 24, 2021

Cooley advised Nykode Therapeutics in its license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases. 

Under the terms of the agreement, Nykode Therapeutics will receive a $30 million upfront payment and a $20 million equity investment at a premium of 20% on a 30-day volume weighted average price of the Nykode Therapeutics share for the last 30 trading days before the effective date of the agreement. Additionally, Nykode Therapeutics will potentially be eligible to receive more than $875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration, bringing the total potential value of the agreement to more than $925 million, plus royalties.

Lawyers Ken Krisko, Christophe Beauduin, John Forrest, Marya Postner and Hajra Nashin led the Cooley team advising Nykode. 

 

Related contacts

Kay Chandler
Partner, San Diego
Christophe Beauduin
Special Counsel, New York
John Forrest
Associate, Boston
Marya Postner
Partner, Palo Alto
Hajra Nashin
Associate, San Diego

Related Practices & Industries